Neoantigen & Personalized Cancer Vaccines Market to Surge at 24.7% CAGR, Reaching USD 5.5 Billion by 2035

According to the MarketGenics report, the global neoantigen & personalized cancer vaccines market is likely to grow from USD 0.6 Billion in 2025 to USD 5.5 Billion in 2035 at a highest CAGR of 24.7% during the time period. The global neoantigen and personalized cancer vaccines market is advancing at a rapid pace as precision oncology and personalised immunotherapy are emerging as a key focus of cancer therapy. Advances in neoantigen prediction software, next-generation sequencing, AI-assisted immune-profiling and mRNA-based vaccine platforms are making it possible to deliver highly personalized therapies based on tumor mutation profile. These technologies enhance immune-activation, tumor-specific targeting, and prolong clinical responses.

Customized cancer-immunization protocols are transitioning beyond scientific idea to clinical practice, which is aided by breakthroughs in genomics, AI-driven antigen-discovery platforms, and automated vaccine-manufacturing systems. Digital bioinformatics tools and cloud-based immunology systems are reducing the development cost and increasing the design accuracy. For instance, in January 2025, the University of Liverpool collaborated with myNEO Therapeutics to facilitate a Phase 1 individualized cancer vaccine trial of non-small cell lung cancer, showing a rapid transition to clinical use of personalized cancer-vaccine technology.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Neoantigen & Personalized Cancer Vaccines Market Research Report: https://marketgenics.co/press-releases/neoantigen-personalized-cancer-vaccines-market-19334

Key Driver, Restraint, and Growth Opportunity Shaping the Global Neoantigen & Personalized Cancer Vaccines Market

The increased use of precision immunotherapy is driving the need of neoantigen and personalized cancer vaccines. Neoantigen prediction using AIs, next-gen sequencing, and mRNA platforms are allowing the use of highly targeted immune activation that can be more stable clinically. For instance, In March 2025, scientists at the Icahn School of Medicine at Mount Sinai announced that a personalized neoantigen vaccine displayed strong T-cell responses in a Phase 1 study of advanced cancers, adding to the therapeutic promise of personalized cancer-vaccination strategies. The momentum in the global market is propelled by the increasing programs in oncology and the growing investments in the personalized immunotherapy pipelines.

The neoantigen and personalized cancer vaccines market is still challenged by high development and manufacturing costs. Individual sequencing, complicated vaccine manufacturing, and cold-chain logistics drive up total costs, restricting access in cost effective areas. The changing regulatory directions and the necessity of the high-level diagnostic and research facilities also hinder adoption, especially in emerging markets.

Increased commercialization opportunities are being increased by expansion of decentralized production, automated bioinformatics and modular clinical trials. New opportunities are being generated by growing investments, biotech-academic collaborations and incorporation of combination therapies. Early-stage immunization and minimal-residual-disease management are also in favor of long-term development of personalized cancer vaccines.

To know more about the Neoantigen & Personalized Cancer Vaccines Market - Download our Sample Report: https://marketgenics.co/download-report-sample/neoantigen-personalized-cancer-vaccines-market-19334

Regional Analysis of Global Neoantigen & Personalized Cancer Vaccines Market

The neoantigen and personalized cancer vaccines market is dominated by North America with its advanced oncology infrastructure, extensive use of personalized immunotherapies, and impressive concentration on precision cancer treatment. Established hospitals and cancer centers are also adopting the use of neoantigen-based vaccines together with the traditional treatment to enhance the immune targeting, clinical response, and survival of a patient. An advanced regulatory system, ecosystem of R&D, and effective ventures among biotech companies and educational centers in addition to the rising integration of AI-powered neoantigen prediction and high-throughput sequencing systems also support regional leadership.

The Asia-Pacific is becoming the most rapidly developing region due to the accelerated modernization of healthcare, the rise of cancer rates, and the growing interest in investing in precision oncology. The adoption is speeding up due to expansion of biotech manufacturing facilities, upgrading of hospital infrastructures in China, India, Japan, and South Korea, and government efforts which are favourable towards the development of immunotherapy. Collaborations in strategic partnerships, transfer of technology, and clinical trials are making the region a prime growth center of personalized cancer vaccines in the world.

Prominent players operating in the global neoantigen & personalized cancer vaccines market are Advaxis, Inc., Agenus Inc., Bavarian Nordic A/S, BioNTech SE, Bristol Myers Squibb Company, CureVac N.V., Genocea Biosciences, Inc., Gradalis, Inc., Gritstone bio, Inc., Immunocore Holdings plc, Lytix Biopharma, Merck & Co., Inc., Moderna, Inc., Nektar Therapeutics, Nouscom AG, Novartis AG, OSE Immunotherapeutics, Personalis, Inc., Pfizer Inc., Repertoire Immune Medicines, Transgene SA, Vaccibody AS, Other Key Players.

Buy Now: https://marketgenics.co/buy/neoantigen-personalized-cancer-vaccines-market-19334

Recent Development and Strategic Overview:

In March 2025, Everest Medicines announced that the first patient has been dosed with its internally-developed personalized mRNA cancer vaccine, EVM16, at Peking University Cancer Hospital, in the first-in-human investigator-initiated trial (EVM16CX01) in collaboration with Fudan University Shanghai Cancer Center.

In March 2024, NEC Corporation declared that it is furthering its partnership with Transgene and BostonGene Corporation in the Phase I/II clinical trial of the individualized neoantigen-based cancer vaccine TG4050. The partnership will combine tumour-molecular profiling and NGS analytics developed by BostonGene with myvac viral vector platform developed by Transgene and neoantigen prediction system developed by AI created by NEC to simplify the process of vaccine development in patients with head and neck cancer.

Get a preview of our Neoantigen & Personalized Cancer Vaccines Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/neoantigen-personalized-cancer-vaccines-market-19334

Key Trend: mRNA Platform Dominance Enables Rapid Manufacturing and Multi-Epitope Targeting

Messenger RNA (mRNA) vaccines have become the most promising technology in the development of neoantigen-based personalized cancer vaccinations due to their flexibility, fast-design capability, and capacity to produce numerous patient-specific neoantigens in one vaccine. This multi-epitope targeting provides extensive immune responses to tumor heterogeneity and could potentially diminish chances of immune escape, as is the case with single-epitope approaches.

The cellular uptake and potent T-cell activation is increased by lipid nanoparticle (LNP) delivery systems. For instance, in July 2025, The University of Tokyo created a neoantigen (neoAg) mRNA vaccine that showed strong antitumor effects in gastric cancer cells, especially when used in combination with conventional anti-PD-1 therapy. These systems enhance immunogenicity and lead to clinical potential in various types of cancers.

Multi-epitope mRNA vaccines elicit long-lasting neoantigen-specific T-cell immunity and delay recurrence or death in high-grade cancers. The existing mRNA production facilities and previous regulatory experience streamline quicker development and scalable production, entrenching mRNA technology as a core driver of innovation and expansion in the neoantigen and personalized cancer vaccines market.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

This release was published on openPR.